Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for the differentiation of human preadipocytes into adipocytes

a technology of adipocytes and compositions, applied in the field of adipocyte biology, can solve the problems of affecting the differentiation of human adipocytes into adipocytes, and affecting the differentiation of human adipocytes and adipose metabolism,

Inactive Publication Date: 2005-07-21
ARTECEL SCIENCE INC
View PDF36 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides methods and compositions for converting human preadipocytes into adipocytes with specific characteristics. The methods involve incubating isolated human preadipocytes in a medium containing glucose, a cyclic AMP inducer, a glucocorticoid or glucocorticoid analogue, insulin or an insulin analogue, and a PPARγ agonist or RXR agonist. The invention also provides methods for determining the effects of a compound on the differentiation of human preadipocytes, identifying novel polypeptides secreted from human adipocytes, and transfecting cultured human adipocytes. These methods and compositions have applications in drug discovery and the study of diabetes, obesity, and cardiovascular disease.

Problems solved by technology

However, insulin is not convenient to use in that it must be injected 2-4 times per day and must be stored properly to prevent loss of efficacy.
Unfortunately, there are safety concerns related to the use of these drugs.
However, studies to find such molecules have been hampered by a lack of reproducible human in vitro cell systems.
Consequently, studies on human adipocytes and adipose metabolism have been hampered by the lack of a preadipocyte cell culture that can be reproducibly induced to differentiate into adipocytes at high efficiency.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for the differentiation of human preadipocytes into adipocytes
  • Methods and compositions for the differentiation of human preadipocytes into adipocytes
  • Methods and compositions for the differentiation of human preadipocytes into adipocytes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Differentiation of Human Preadipocytes into Adipocytes

[0095] Human preadipocytes were isolated from adipose tissue removed by liposuction surgery according to the procedures previously described by Rodbell and Hauner (Rodbell (1967) and (1974); Hauner, supra). Preadipocytes from the stroma-vascular fraction were resuspended in preadipocyte medium (DME-Ham's F-10, 1:1 (v / v), 10% FBS, and penicillin-streptomycin-fungizone) and plated at 25,000 cells / well in each of the wells of a 96 well plate (150 μl / well). The cells were then placed in a 37° C. 5% CO2 incubator and allowed to settle overnight. The following day, all of the medium was removed and replaced with 150 μl differentiation medium (Dulbecco's Modified Eagle Medium / Ham's F-10 Nutrient Broth (1:1, vol / vol), 15 mM HEPES buffer, pH 7.4, 33 μM biotin, 17 μM pantothenate, 0.2 mM isobutylmethylxanthine, 100 nM insulin, 1 μM dexamethasone, 1 μM BRL 49653 (diluted into medium from a 100×DMSO stock solution), 10% (vol / vol) fetal bov...

example 2

Identification of Compounds that Enhance Preadipocyte Differentiation to Adipocytes

[0101] To test the ability of a compound to stimulate differentiation of preadipocytes to adipocytes, the procedures of Example 1 were followed with the following modifications. BRL 49653 was omitted from the differentiation medium and replaced with the compound to be tested or with vehicle alone as a negative control. BRL 49653 was used as a positive control. Various concentrations of BRL49653 in DMEM / F-10 medium containing 3% fetal calf serum, 100 nM insulin, 1 μM dexamethasone, and 0.2 mM isobutylmethylxanthine were incubated with the cells for 3 days and then adipocyte media without BRL49653. After 9 days the cells were washed, fixed and stained with Oil Red O as described herein. The Oil Red O was extracted, quantitated spectrophotometrically and the results plotted as BRL49653 concentration versus optical density (OD). FIG. 3 illustrates the dose responsive effect of BRL49653 on the ability to...

example 3

Identification of Glucocorticoids and Glucocorticoid Analogues

[0102] To test the ability of a compound to act as a glucocorticoid and / or glucocorticoid analogue, the procedures of Example 1 were followed with the following modifications. Human preadipocytes were isolated and cultured in DMEM / F-10 medium containing 3% fetal calf serum, 100 nM insulin, 0.2 mM isobutylmethylxanthine with increasing concentrations of dexamethasone under the conditions described herein for 3 days. The media was then replaced with DMEM / F10 (1:1) containing 3% fetal calf serum, 100 nM insulin and increasing concentrations of dexamethosome. The cells were fed with this medium every three days for 12 days. Cells were then washed, fixed and stained with Oil Red O as described above. FIG. 4 illustrates the ability of dexamethasone to stimulate differentiation in a dose-dependent manner, as measured by lipid accumulation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
ODaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods and compositions for the consistent and quantitative differentiation of human preadipocytes isolated from adipose tissue into adipocytes bearing biochemical, genetic, and physiological characteristics similar to that observed in isolated primary adipocytes. The methods of the invention comprise incubating isolated human preadipocytes, plated at least about 25,000 cells / cm2, in a medium containing, glucose, a cyclic AMP inducer such as isobutylmethylxanthine or forskolin, a glucocorticoid or glucocorticoid analogue, insulin or an insulin analogue and a PPARγ agonist or a RXR agonist. The compositions of the invention include media for the differentiation of human preadipocytes, human adipocytes differentiated by the methods of the invention and transfected adipocytes. The present invention also provides methods for determining the ability of a compound to affect the differentiation of human preadipocytes to adipocytes, for determining the ability of a compound to act as a PPARγ antagonist. a glucocorticoid, a glucocoticoid analogue, or an insulin analogue, for transfecting cultured human adipocytes, and as a means to identify novel polypeptides secreted from human adipocytes into the conditioned medium. The methods and compositions have use in the drug discovery of compounds having relevance to the disease states of diabetes, obesity, and cardiovascular disease and in the studies of these diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of U.S. application Ser. No. 09 / 240,029, filed Jan. 29, 1999 which is herein incorporated by reference.[0002] FIELD OF THE INVENTION [0003] The invention is drawn to the field of adipocyte biology. Methods and compositions are provided for the differentiation of human preadipocytes into adipocytes. BACKGROUND OF THE INVENTION [0004] Non-insulin dependent diabetes mellitus (NIDDM) afflicts 4-5 million Americans every year. NIDDM is treated predominately with insulin. However, insulin is not convenient to use in that it must be injected 2-4 times per day and must be stored properly to prevent loss of efficacy. Other drugs used to treat NIDDM include troglitazone (Rezulin™), a PPARγ agonist, Glucophage™ and sulfonylureas. Unfortunately, there are safety concerns related to the use of these drugs. The identification of safe, effective, orally available drugs for the treatment of NIDDM would greatly enhance t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61L27/38C12N5/077
CPCA61L27/38C12N5/0653C12N2501/01C12N2503/02C12N2501/385C12N2501/39C12N2501/33
Inventor HALVORSEN, YUAN-DI C.WILKISON, WILLIAM O.
Owner ARTECEL SCIENCE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com